University of Maryland, Baltimore
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).
University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.
University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.
Top-decile sponsor footprint
University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
560 total, page 3 of 12
Improving Outcomes for Patients With Life-Threatening Neurologic Illness
NCT04189471
PKD Clinical and Translational Core Study
NCT01873235
Blood Donor CVD 5000
NCT03971669
Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy
NCT07320989
Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health
NCT07116226
E-cigarette Switching Older Adults
NCT06534905
Diclofenac as a KMO Inhibitor
NCT06029296
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
NCT05968144
Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia
NCT06129825
Minimally Displaced Femoral Neck Fracture Pilot Study
NCT05947058
Ketogenic Diet in People With Schizophrenia
NCT05968638
Screening for Atrial Fibrillation in Elderly Women Older Than 70 Years
NCT05444335
Time-Restricted Eating to Address Persistent Cancer-Related Fatigue
NCT05256888
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
NCT05316584
Symptomatic Carotid Outcomes Registry
NCT05300737
Bringing Health Home
NCT05160701
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain
NCT04851301
MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia
NCT04579692
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
NCT04609280
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
NCT04150900
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT04098081
Progressive Rehabilitation Therapy in Patients With Advanced Lung Disease
NCT03562728
Vasopressin and Pain Perception in the Brain
NCT03446456
Vital Pulp Treatment in Primary Teeth
NCT02298504
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
NCT03221309
Assessing The Effects of Exercise, Protein, and Electric Stimulation On Intensive Care Unit Patients Outcomes
NCT02509520
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults
NCT03970304
GLP-1 and Hypoglycemia
NCT01858896
Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors
NCT05326633
Pharmacogenetics of Response to Sitagliptin (PRS)
NCT06813014
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
NCT07537413
OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis
NCT07221799
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
NCT07615075
Virtual Reality for SCD VOC
NCT07674277
GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung
NCT07679607
DockTales for Chronic Pain
NCT07680894
Development of an Opioid Withdrawal Clinical Outcome Assessment
NCT07094672
Ketones for Opioid Craving
NCT07128524
Continuous Glucose Monitors (CGMs) and Readmission Rates
NCT07221812
Malaria CVD 36000; Gates INV090205
NCT07558122
Feasibility, Usability and Preliminary Efficacy of Home-based FES Fro Adhesive Capsulitis
NCT07227662
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer
NCT07374796
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
NCT07620561
Decision Aid Efficacy in Low Risk Thyroid Cancer
NCT07536412
Transcriptomic Profile Changes in Benign Tracheal Stenosis: Wedge Resection vs. Radial Incision
NCT07463742
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
NCT07528430
Biotivity A-C Membrane Socket Preservation Study
NCT07091448
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
NCT07221708
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
NCT07415681
Intranasal LAIV Mucosal Immunity Examination
NCT07093281
What is open in the University of Maryland, Baltimore pipeline
103 recruiting of 560 indexed (18% open); 332 completed (59%).
Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (14 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Maryland, Baltimore: open-pipeline peers nationwide
Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 560 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this University of Maryland, Baltimore page
560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.
- 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets.Report a data error.